Counterfeit Pills, Synthetic Drugs Drive New Phase of U.S. Drug Crisis, Officials Warn
WASHINGTON — A surge in counterfeit prescription pills and emerging synthetic drugs is worsening the U.S. drug crisis, officials and experts told lawmakers, warning that the rapidly evolving threat is outpacing current enforcement and public health responses.
At a House Energy and Commerce subcommittee hearing, lawmakers examined a package of 14 bills aimed at curbing illicit drug trafficking, tightening controls on new substances, and expanding access to addiction treatment.
Witnesses described a drug landscape that has shifted dramatically from traditional narcotics to highly potent synthetic mixtures, often produced in clandestine labs and disguised as legitimate medications.
“The most urgent threat today is counterfeit prescription pills,” said Scott Oulton, a former Drug Enforcement Administration forensic chief. He warned that such pills are mass-produced by criminal networks with “no quality control or consistency,” even when they appear identical.
Two pills that look the same “can contain wildly different amounts of deadly drugs such as fentanyl, nitazenes, xylazine,” he said, underscoring the unpredictability driving fatal overdoses.
Law enforcement officials said the growing combination of substances in the drug supply has made the situation more dangerous. Seminole County, Florida, Sheriff Dennis Lemma told lawmakers that today’s drugs are “more potent, unpredictable, and deceptive” than in previous decades.
Users often believe they are taking legitimate prescription medication but instead ingest substances laced with fentanyl or other synthetic compounds. “A single dose is fatal” in some cases, Lemma said.
One emerging concern is xylazine, a veterinary sedative increasingly found mixed with opioids. Because it is not an opioid, naloxone — commonly used to reverse overdoses — “does not reverse its effects,” complicating emergency response efforts.
Another substance drawing attention is a synthetic compound known as 7OH, which Lemma said is being marketed as a natural product despite significant risks of addiction and overdose.
Lawmakers argued that stronger enforcement tools are needed to keep pace, with proposed legislation seeking to classify substances such as xylazine and nitazenes under the Controlled Substances Act.
However, some public health experts urged caution. Nabarun Dasgupta, a researcher at the University of North Carolina, warned that aggressively restricting one drug can quickly lead to the emergence of another. He pointed to recent data showing xylazine being replaced in some areas by a similar compound, medetomidine.
“The wrong schedule can make a bad situation worse,” Dasgupta said, noting that new substances can introduce different and sometimes more severe health risks.
Health officials also emphasized the need to sustain recent progress in reducing overdose deaths. Yngvild Olsen, a former federal addiction official, said fatalities have declined from pandemic-era highs but warned that gains could reverse without continued investment in treatment.
“Congress must work to sustain this momentum and not move backwards,” she said, highlighting medications such as methadone and buprenorphine as key tools in reducing overdose risk.
The hearing underscored a broader divide among policymakers, with some prioritizing law enforcement and supply-side controls while others advocate for expanded treatment, harm reduction, and stable funding for public health programs.
Witnesses agreed that the pace of change in the illicit drug market is accelerating. Oulton noted that new tools, including wastewater testing, can provide near real-time data on drug use trends and help authorities respond more quickly.
The opioid crisis in the United States has evolved over the past two decades, shifting from prescription painkillers to heroin and, more recently, to synthetic opioids such as fentanyl. The rise of counterfeit pills and new chemical compounds marks a more complex and unpredictable phase.
Although overdose deaths have begun to decline, officials warned that increasingly potent and harder-to-detect synthetic drugs continue to pose a serious challenge for both law enforcement and public health systems. (Source: IANS)
